## Pablo Perel

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9585971/publications.pdf

Version: 2024-02-01

180 papers 20,728 citations

24978 57 h-index 137 g-index

197 all docs

197 docs citations

197 times ranked

24426 citing authors

#	Article	IF	Citations
1	Implementing Single-Pill Combination Therapy for Hypertension: A Scoping Review of Key Health System Requirements in 30 Low- and Middle-Income Countries. Global Heart, 2022, 17, 6.	0.9	8
2	Chronic NCD care in crises: A qualitative study of global experts' perspectives on models of care for hypertension and diabetes in humanitarian settings. Journal of Migration and Health, 2022, 5, 100094.	1.6	9
3	Are We There Yet? Exploring the Use of Single-Pill Combination Therapy in the Management of Raised Blood Pressure in Australia. Heart Lung and Circulation, 2022, , .	0.2	О
4	Scaling up the primary health integrated care project for chronic conditions in Kenya: study protocol for an implementation research project. BMJ Open, 2022, 12, e056261.	0.8	3
5	Burden of non-communicable diseases among adolescents aged 10–24 years in the EU, 1990–2019: a systematic analysis of the Global Burden of Diseases Study 2019. The Lancet Child and Adolescent Health, 2022, 6, 367-383.	2.7	48
6	Assessing the potential of wearable health monitors for health system strengthening in low- and middle-income countries: a prospective study of technology adoption in Cambodia. Health Policy and Planning, 2022, 37, 943-951.	1.0	5
7	Implementation of fixed-dose combination therapy for secondary prevention of atherosclerotic cardiovascular disease among Syrian refugees in Lebanon: a qualitative evaluation. BMC Health Services Research, 2022, 22, .	0.9	2
8	Cardiovascular Risk Factors and Clinical Outcomes among Patients Hospitalized with COVID-19: Findings from the World Heart Federation COVID-19 Study. Global Heart, 2022, 17, .	0.9	12
9	The World Heart Observatory: Harnessing the Power of Data for Cardiovascular Health. Global Heart, 2022, 17, .	0.9	2
10	Models of care for non-communicable diseases for displaced populations in Iraq: a scoping review. Conflict and Health, 2022, 16, .	1.0	0
11	Risk scoring for the primary prevention of cardiovascular disease. The Cochrane Library, 2021, 2021, CD006887.	1.5	70
12	Clinical outcomes in a primary-level non-communicable disease programme for Syrian refugees and the host population in Jordan: A cohort analysis using routine data. PLoS Medicine, 2021, 18, e1003279.	3.9	11
13	World Heart Federation Roadmap on Atrial Fibrillation – A 2020 Update. Global Heart, 2021, 16, 41.	0.9	39
14	<i>âe What the herbal medicine can do for me in a week, the orthodox does in a yearâ ™:</i> Perceived efficacy of local alternative therapies influences medication adherence in patients with atherosclerotic cardiovascular disease. Health Expectations, 2021, 24, 444-455.	1.1	4
15	Models of care for patients with hypertension and diabetes in humanitarian crises: a systematic review. Health Policy and Planning, 2021, 36, 509-532.	1.0	15
16	Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults. The Cochrane Library, 2021, 2021, CD012675.	1.5	21
17	External validation of a deep learning electrocardiogram algorithm to detect ventricular dysfunction. International Journal of Cardiology, 2021, 329, 130-135.	0.8	36
18	MSF experiences of providing multidisciplinary primary level NCD care for Syrian refugees and the host population in Jordan: an implementation study guided by the RE-AIM framework. BMC Health Services Research, 2021, 21, 381.	0.9	12

#	Article	IF	CITATIONS
19	Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nature Reviews Cardiology, 2021, 18, 785-802.	6.1	515
20	Exploring Barriers to Medication Adherence Using COM-B Model of Behaviour Among Patients with Cardiovascular Diseases in Low- and Middle-Income Countries: A Qualitative Study. Patient Preference and Adherence, 2021, Volume 15, 1359-1371.	0.8	7
21	An investment case for the prevention and management of rheumatic heart disease in the African Union 2021–30: a modelling study. The Lancet Global Health, 2021, 9, e957-e966.	2.9	40
22	Efficacy and Safety of Text Messages Targeting Adherence to Cardiovascular Medications in Secondary Prevention: TXT2HEART Colombia Randomized Controlled Trial. JMIR MHealth and UHealth, 2021, 9, e25548.	1.8	9
23	Clinical burden, risk factor impact and outcomes following myocardial infarction and stroke: A 25-year individual patient level linkage study. Lancet Regional Health - Europe, The, 2021, 7, 100141.	3.0	18
24	Process evaluation of complex interventions in chronic and neglected tropical diseases in low- and middle-income countries—a scoping review protocol. Systematic Reviews, 2021, 10, 244.	2.5	3
25	User experiences and perceptions of health wearables: an exploratory study in Cambodia. Global Health Research and Policy, 2021, 6, 33.	1.4	5
26	World Heart Day 2021: COVID-19, digital health, and tackling cardiovascular disease. Lancet, The, 2021, 398, 1467-1468.	6.3	12
27	World Heart Federation Roadmap for Hypertension – A 2021 Update. Global Heart, 2021, 16, 63.	0.9	56
28	Influenza Vaccination for the Prevention of Cardiovascular Disease in the Americas: Consensus document of the Inter-American Society of Cardiology and the Word Heart Federation. Global Heart, 2021, 16, 55.	0.9	14
29	The World Heart Federation Global Study on COVID-19 and Cardiovascular Disease. Global Heart, 2021, 16, 22.	0.9	10
30	Left ventricular systolic dysfunction predicted by artificial intelligence using the electrocardiogram in Chagas disease patients–The SaMi-Trop cohort. PLoS Neglected Tropical Diseases, 2021, 15, e0009974.	1.3	3
31	Community involvement in the development and implementation of chronic condition programmes across the continuum of care in high- and upper-middle income countries: A systematic review. Health Policy, 2020, 124, 419-437.	1.4	10
32	Cohort Profile: The Cohorts Consortium of Latin America and the Caribbean (CC-LAC). International Journal of Epidemiology, 2020, 49, 1437-1437g.	0.9	6
33	Lessons learned about co-creation: developing a complex intervention in rural Peru. Global Health Action, 2020, 13, 1754016.	0.7	30
34	Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. The Lancet Global Health, 2020, 8, e1003-e1017.	2.9	760
35	Reducing Premature Cardiovascular Mortality By 2025: The World Heart Federation Roadmap. Global Heart, 2020, 10, 97.	0.9	7
36	Adapting the World Heart Federation Roadmaps at the National Level: Next Steps and Conclusions. Global Heart, 2020, 10, 135.	0.9	7

#	Article	IF	Citations
37	World Heart Federation Emerging Leaders Program: An Innovative Capacity Building Program to Facilitate the 25 $\tilde{A}-25$ Goal. Global Heart, 2020, 10, 229.	0.9	7
38	The Cochrane Heart at <i>Global Heart</i> . Global Heart, 2020, 9, 511.	0.9	0
39	WHF IASC Roadmap on Chagas Disease. Global Heart, 2020, 15, 26.	0.9	<b>7</b> 5
40	Inclusion in the World Health Organization Model List of Essential Medicines of Non-Vitamin K Anticoagulants for Treatment of Non-Valvular Atrial Fibrillation: A Step Towards Reducing the Burden of Cardiovascular Morbidity and Mortality. Global Heart, 2020, 15, 52.	0.9	11
41	Management of Cardiovascular Disease Patients With Confirmed or Suspected COVID-19 in Limited Resource Settings. Global Heart, 2020, 15, 44.	0.9	11
42	Implementing Fixed Dose Combination Medications for the Prevention and Control of Cardiovascular Diseases. Global Heart, 2020, 15, 57.	0.9	17
43	COVID-19: Implications for People with Chagas Disease. Global Heart, 2020, 15, 69.	0.9	39
44	Barriers and facilitators to the implementation of a community-based hypertension improvement project in Ghana: a qualitative study of ComHIP. BMC Health Services Research, 2020, 20, 67.	0.9	9
45	The Heart in the Time of the â€~Coronavirus'. Global Heart, 2020, 15, 24.	0.9	4
46	The comparative effectiveness of fourthâ€line drugs in resistant hypertension: An application in electronic health record data. Pharmacoepidemiology and Drug Safety, 2019, 28, 1267-1277.	0.9	8
47	Response by Prabhakaran et al to Letter Regarding Article, "Effectiveness of an mHealth-Based Electronic Decision Support System for Integrated Management of Chronic Conditions in Primary Care: The mWellcare Cluster-Randomized Controlled Trial― Circulation, 2019, 139, e1039.	1.6	10
48	Health system challenges to hypertension and related non-communicable diseases prevention and treatment: perspectives from Ghanaian stakeholders. BMC Health Services Research, 2019, 19, 693.	0.9	32
49	Non-communicable diseases in sub-Saharan Africa: a scoping review of large cohort studies. Journal of Global Health, 2019, 9, 020409.	1.2	68
50	Cardiovascular Disease among Syrian refugees: a descriptive study of patients in two Médecins Sans FrontiÃ'res clinics in northern Lebanon. Conflict and Health, 2019, 13, 37.	1.0	13
51	World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. The Lancet Global Health, 2019, 7, e1332-e1345.	2.9	554
52	Forty years since Alma-Ata: do we need a new model for noncommunicable diseases?. Journal of Global Health, 2019, 9, 010316.	1.2	11
53	Can a nurse-led community-based model of hypertension care improve hypertension control in Ghana? Results from the ComHIP cohort study. BMJ Open, 2019, 9, e026799.	0.8	26
54	The burden of diabetes and use of diabetes care in humanitarian crises in low-income and middle-income countries. Lancet Diabetes and Endocrinology, the, 2019, 7, 638-647.	5.5	51

#	Article	IF	Citations
55	Evaluation of the efficacy and safety of text messages targeting adherence to cardiovascular medications in secondary prevention: the txt2heart Colombia randomised controlled trial protocol. BMJ Open, 2019, 9, e028017.	0.8	4
56	Management of diabetes and associated costs in a complex humanitarian setting in the Democratic Republic of Congo: a retrospective cohort study. BMJ Open, 2019, 9, e030176.	0.8	13
57	Acceptability and feasibility of a national essential medicines list in Canada: a qualitative study of perceptions of decision-makers and policy stakeholders. Cmaj, 2019, 191, E1093-E1099.	0.9	5
58	Effectiveness of an mHealth-Based Electronic Decision Support System for Integrated Management of Chronic Conditions in Primary Care. Circulation, 2019, 139, 380-391.	1.6	62
59	The Road to 25×25: Update on WHF CVD Roadmaps. Global Heart, 2019, 12, 269.	0.9	1
60	Clinical Impact of the Polypill for Cardiovascular Prevention in Latin America: A Consensus Statement of the Inter-American Society of Cardiology. Global Heart, 2019, 14, 3.	0.9	13
61	Cardiovascular Disease Prognostic Models in Latin America and the Caribbean: A Systematic Review. Global Heart, 2019, 14, 81.	0.9	11
62	Access to Essential Medicines for Circulatory Diseases: A Call to Action. Global Heart, 2019, 14, 399.	0.9	3
63	World Heart Federation Roadmap for Heart Failure. Global Heart, 2019, 14, 197.	0.9	67
64	At the heart of the conflict. Heart, 2019, 105, 1382-1383.	1.2	3
65	Cardiovascular risk prediction in India: Comparison of the original and recalibrated Framingham prognostic models in urban populations Wellcome Open Research, 2019, 4, 71.	0.9	8
66	User Preferences and Persona Design for an mHealth Intervention to Support Adherence to Cardiovascular Disease Medication in Singapore: A Multi-Method Study. JMIR MHealth and UHealth, 2019, 7, e10465.	1.8	28
67	Perspectives on Acceptance and Use of a Mobile Health Intervention for the Prevention of Atherosclerotic Cardiovascular Disease in Singapore: Mixed-Methods Study. JMIR MHealth and UHealth, 2019, 7, e11108.	1.8	8
68	Cardiovascular risk prediction in India: Comparison of the original and recalibrated Framingham prognostic models in urban populations Wellcome Open Research, 2019, 4, 71.	0.9	2
69	Inequalities in the use of secondary prevention of cardiovascular disease by socioeconomic status: evidence from the PURE observational study. The Lancet Global Health, 2018, 6, e292-e301.	2.9	73
70	Improving medication adherence in patients with cardiovascular disease: a systematic review. Heart, 2018, 104, 1238-1243.	1.2	37
71	Integrating cardiovascular diseases, hypertension, and diabetes with HIV services: a systematic review. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 103-115.	0.6	85
72	Access and adherence to medications for the primary and secondary prevention of atherosclerotic cardiovascular disease in Singapore: a qualitative study. Patient Preference and Adherence, 2018, Volume 12, 2481-2498.	0.8	13

#	Article	IF	CITATIONS
73	Development of mWellcare: an mHealth intervention for integrated management of hypertension and diabetes in low-resource settings. Global Health Action, 2018, 11, 1517930.	0.7	34
74	Cochrane corner: text messaging to improve adherence to drugs for secondary prevention of cardiovascular disease. Heart, 2018, 104, 1814-1816.	1.2	3
75	Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults. The Cochrane Library, 2018, 6, CD012675.	1.5	66
76	The economic burden of cardiovascular disease and hypertension in low- and middle-income countries: a systematic review. BMC Public Health, 2018, 18, 975.	1.2	268
77	Diagnostic accuracy of the Finnish Diabetes Risk Score (FINDRISC) for undiagnosed T2DM in Peruvian population. Primary Care Diabetes, 2018, 12, 517-525.	0.9	56
78	The effectiveness of smoking cessation, physical activity/diet and alcohol reduction interventions delivered by mobile phones for the prevention of non-communicable diseases: A systematic review of randomised controlled trials. PLoS ONE, 2018, 13, e0189801.	1.1	88
79	Assessing the influence of health systems on Type 2 Diabetes Mellitus awareness, treatment, adherence, and control: A systematic review. PLoS ONE, 2018, 13, e0195086.	1.1	61
80	Challenges and Opportunities to Scale Up Cardiovascular Disease Secondary Prevention in Latin America and the Caribbean. Global Heart, 2018, 13, 83.	0.9	6
81	Roadmap to Achieve 25% Hypertension Control in Africa by 2025. Global Heart, 2018, 13, 45.	0.9	59
82	Global Atlas of Cardiovascular Disease 2000-2016: The Path to Prevention and Control. Global Heart, 2018, 13, 143.	0.9	246
83	Uses of polypills for cardiovascular disease and evidence to date. Lancet, The, 2017, 389, 1055-1065.	<b>6.</b> 3	85
84	Mobile phone text messaging to improve medication adherence in secondary prevention of cardiovascular disease. The Cochrane Library, 2017, 2017, CD011851.	1.5	85
85	Integrating HIV and substance use services: a systematic review. Journal of the International AIDS Society, 2017, 20, 21585.	1.2	76
86	Protocol for the mWellcare trial: a multicentre, cluster randomised, 12-month, controlled trial to compare the effectiveness of mWellcare, an mHealth system for an integrated management of patients with hypertension and diabetes, versus enhanced usual care in India. BMJ Open, 2017, 7, e014851.	0.8	20
87	Health systems facilitators and barriers to the integration of HIV and chronic disease services: a systematic review. Health Policy and Planning, 2017, 32, iv13-iv26.	1.0	60
88	Evaluation of a community-based hypertension improvement program (ComHIP) in Ghana: data from a baseline survey. BMC Public Health, 2017, 17, 368.	1.2	32
89	Diabetes care in a complex humanitarian emergency setting: a qualitative evaluation. BMC Health Services Research, 2017, 17, 431.	0.9	31
90	Interventions and approaches to integrating HIV and mental health services: a systematic review. Health Policy and Planning, 2017, 32, iv27-iv47.	1.0	98

#	Article	IF	Citations
91	Prognosis of undiagnosed chest pain: linked electronic health record cohort study. BMJ: British Medical Journal, 2017, 357, j1194.	2.4	38
92	Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults. The Cochrane Library, 2017, , .	1.5	6
93	Are cardiovascular risk factors also associated with the incidence of atrial fibrillation?. Thrombosis and Haemostasis, 2017, 117, 837-850.	1.8	128
94	WHF Emerging Leaders Program. European Heart Journal, 2017, 38, 2800-2803.	1.0	1
95	World Heart Federation Cholesterol Roadmap. Global Heart, 2017, 12, 179.	0.9	30
96	The World Heart Federation Roadmap for Nonvalvular Atrial Fibrillation. Global Heart, 2017, 12, 273.	0.9	35
97	Atrial fibrillation: the current epidemic. Journal of Geriatric Cardiology, 2017, 14, 195-203.	0.2	208
98	Integrating cervical cancer with HIV healthcare services: A systematic review. PLoS ONE, 2017, 12, e0181156.	1.1	56
99	EZSCAN for undiagnosed type 2 diabetes mellitus: A systematic review and meta-analysis. PLoS ONE, 2017, 12, e0187297.	1.1	5
100	Roadmap to achieve 25% hypertension control in Africa by 2025. Cardiovascular Journal of Africa, 2017, 28, 261-272.	0.2	62
101	The Development of mWellcare, an mHealth System for the Integrated Management of Hypertension and Diabetes in Primary Care. Studies in Health Technology and Informatics, 2017, 245, 1230.	0.2	1
102	Towards sustainable partnerships in global health: the case of the CRONICAS Centre of Excellence in Chronic Diseases in Peru. Globalization and Health, 2016, 12, 29.	2.4	10
103	A 10-year prognostic model for patients with suspected angina attending a chest pain clinic. Heart, 2016, 102, 869-875.	1.2	10
104	The Heart of 25 by 25: Achieving the Goal of Reducing Global and Regional Premature Deaths From Cardiovascular Diseases and Stroke. Circulation, 2016, 133, e674-90.	1.6	155
105	â€~Surfing' the cardiovascular epidemic SURF (SUrvey of Risk Factors), a welcome initiative to improve monitoring of patients with coronary heart disease. European Journal of Preventive Cardiology, 2016, 23, 2019-2020.	0.8	0
106	Efficacy and safety of ablation for people with non-paroxysmal atrial fibrillation. The Cochrane Library, 2016, 2016, CD012088.	1.5	33
107	90â€Prognosis in Suspected Angina (PISA): A 10-year Risk Model Developed in A Chest Pain Clinic Cohort. Heart, 2016, 102, A64-A65.	1.2	0
108	Wealth and cardiovascular health: a cross-sectional study of wealth-related inequalities in the awareness, treatment and control of hypertension in high-, middle- and low-income countries. International Journal for Equity in Health, 2016, 15, 199.	1.5	67

#	Article	IF	CITATIONS
109	The Heart of 25 by 25: Achieving the Goal of Reducing Global and Regional Premature Deaths From Cardiovascular Diseases and Stroke: A Modeling Study From the American Heart Association and World Heart Federation. Global Heart, 2016, 11, 251.	0.9	26
110	Three Steps to Improve Management of Noncommunicable Diseases in Humanitarian Crises. PLoS Medicine, 2016, 13, e1002180.	3.9	38
111	Haemostatic drugs for traumatic brain injury. The Cochrane Library, 2015, , CD007877.	1.5	1
112	Patients' Knowledge, Attitudes, Behaviour and Health Care Experiences on the Prevention, Detection, Management and Control of Hypertension in Colombia: A Qualitative Study. PLoS ONE, 2015, 10, e0122112.	1.1	71
113	The Effectiveness of Interventions for Non-Communicable Diseases in Humanitarian Crises: A Systematic Review. PLoS ONE, 2015, 10, e0138303.	1.1	63
114	2015 Recommendations for the Management of Polymyalgia Rheumatica: A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative. Arthritis and Rheumatology, 2015, 67, 2569-2580.	2.9	146
115	Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. BMJ, The, 2015, 350, h870-h870.	3.0	532
116	The science of clinical practice: disease diagnosis or patient prognosis? Evidence about "what is likely to happen―should shape clinical practice. BMC Medicine, 2015, 13, 20.	2.3	163
117	2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Annals of the Rheumatic Diseases, 2015, 74, 1799-1807.	0.5	220
118	Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica. Annals of the Rheumatic Diseases, 2015, 74, 1808-1817.	0.5	74
119	Reducing Premature Cardiovascular Morbidity and Mortality in People With Atherosclerotic Vascular Disease: The World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease. Global Heart, 2015, 10, 99.	0.9	82
120	Reducing Cardiovascular Disease Globally: The World Heart Federation's Roadmaps. Global Heart, 2015, 10, 93.	0.9	10
121	Defining Disease Phenotypes Using National Linked Electronic Health Records: A Case Study of Atrial Fibrillation. PLoS ONE, 2014, 9, e110900.	1.1	80
122	Prognostic models for stable coronary artery disease based on electronic health record cohort of 102 023 patients. European Heart Journal, 2014, 35, 844-852.	1.0	111
123	Red Blood Cell Transfusion and Mortality in Trauma Patients: Risk-Stratified Analysis of an Observational Study. PLoS Medicine, 2014, 11, e1001664.	3.9	48
124	Improving the Transparency of Prognosis Research: The Role of Reporting, Data Sharing, Registration, and Protocols. PLoS Medicine, 2014, 11, e1001671.	3.9	112
125	Assessing discriminative ability of risk models in clustered data. BMC Medical Research Methodology, 2014, 14, 5.	1.4	40
126	Thromboprophylaxis for trauma patients. The Cochrane Library, 2013, , CD008303.	1.5	80

#	Article	IF	Citations
127	Models of Mortality Probability in Severe Traumatic Brain Injury: Results of the Modelling by the UK Trauma Registry. Journal of Neurotrauma, 2013, 30, 2021-2030.	1.7	10
128	Tranexamic acid for reducing mortality in emergency and urgent surgery. The Cochrane Library, 2013, 2013, CD010245.	1.5	62
129	Colloids versus crystalloids for fluid resuscitation in critically ill patients. The Cochrane Library, 2013, , CD000567.	1.5	518
130	The Influence of Health Systems on Hypertension Awareness, Treatment, and Control: A Systematic Literature Review. PLoS Medicine, 2013, 10, e1001490.	3.9	134
131	Prognosis Research Strategy (PROGRESS) 3: Prognostic Model Research. PLoS Medicine, 2013, 10, e1001381.	3.9	1,006
132	A Systematic Review of the Relationship between Blood Loss and Clinical Signs. PLoS ONE, 2013, 8, e57594.	1.1	162
133	Tranexamic acid in trauma: we need stronger global health policy. BMJ, The, 2013, 347, f4593-f4593.	3.0	3
134	Prognosis research strategy (PROGRESS) 1: A framework for researching clinical outcomes. BMJ, The, 2013, 346, e5595-e5595.	3.0	450
135	Patient perspectives on the promptness and quality of care of road traffic incident victims in Peru: a cross-sectional, active surveillance study. F1000Research, 2013, 2, 167.	0.8	5
136	Major Cardiovascular Risk Factors in Latin America: A Comparison with the United States. The Latin American Consortium of Studies in Obesity (LASO). PLoS ONE, 2013, 8, e54056.	1.1	100
137	CYP2D6 Genotype and Tamoxifen Response for Breast Cancer: A Systematic Review and Meta-Analysis. PLoS ONE, 2013, 8, e76648.	1.1	43
138	Prediction of outcome after moderate and severe traumatic brain injury. Critical Care Medicine, 2012, 40, 1609-1617.	0.4	549
139	Predicting early death in patients with traumatic bleeding: development and validation of prognostic model. BMJ, The, 2012, 345, e5166-e5166.	3.0	79
140	Prognostic Value of Major Extracranial Injury in Traumatic Brain Injury. Neurosurgery, 2012, 70, 811-818.	0.6	92
141	Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ, The, 2012, 344, e3054-e3054.	3.0	713
142	Colloids versus crystalloids for fluid resuscitation in critically ill patients., 2012, , CD000567.		65
143	Effect of tranexamic acid on mortality in patients with traumatic bleeding: prespecified analysis of data from randomised controlled trial. BMJ, The, 2012, 345, e5839-e5839.	3.0	120
144	Covariate adjustment increased power in randomized controlled trials: an example in traumatic brain injury. Journal of Clinical Epidemiology, 2012, 65, 474-481.	2.4	48

#	Article	IF	Citations
145	CRASH-3 - tranexamic acid for the treatment of significant traumatic brain injury: study protocol for an international randomized, double-blind, placebo-controlled trial. Trials, 2012, 13, 87.	0.7	149
146	Predicting intracranial hemorrhage after traumatic brain injury in low and middle-income countries: A prognostic model based on a large, multi-center, international cohort. BMC Emergency Medicine, 2012, 12, 17.	0.7	22
147	Risk Factors for Vascular Occlusive Events and Death Due to Bleeding in Trauma Patients; an Analysis of the CRASH-2 Cohort. PLoS ONE, 2012, 7, e50603.	1.1	9
148	Avoidable mortality from giving tranexamic acid to bleeding trauma patients: an estimation based on WHO mortality data, a systematic literature review and data from the CRASH-2 trial. BMC Emergency Medicine, 2012, 12, 3.	0.7	95
149	The added value of ordinal analysis in clinical trials: an example in traumatic brain injury. Critical Care, 2011, 15, R127.	2.5	131
150	The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet, The, 2011, 377, 1096-1101.e2.	6.3	950
151	Early administration of tranexamic acid in trauma patients – Authors' reply. Lancet, The, 2011, 378, 28.	6.3	0
152	Feasibility of salt reduction in processed foods in Argentina. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2011, 29, 69-75.	0.6	48
153	Cost-Effectiveness Analysis of Administering Tranexamic Acid to Bleeding Trauma Patients Using Evidence from the CRASH-2 Trial. PLoS ONE, 2011, 6, e18987.	1.1	150
154	CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular Events. JAMA - Journal of the American Medical Association, 2011, 306, 2704.	3.8	420
155	Between-centre differences and treatment effects in randomized controlled trials: A case study in traumatic brain injury. Trials, 2011, 12, 201.	0.7	26
156	Prognostic models for the early care of trauma patients: a systematic review. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2011, 19, 17.	1.1	46
157	Colloids versus crystalloids for fluid resuscitation in critically ill patients. , 2011, , CD000567.		72
158	Thromboprophylaxis for trauma patients. , 2010, 2010, .		4
159	Giving tranexamic acid to reduce surgical bleeding in sub-Saharan Africa: an economic evaluation. Cost Effectiveness and Resource Allocation, 2010, 8, 1.	0.6	44
160	The risk of transfusionâ€ŧransmitted infections in subâ€Saharan Africa. Transfusion, 2010, 50, 433-442.	0.8	123
161	Haemostatic drugs for traumatic brain injury. , 2010, , CD007877.		31
162	Tranexamic acid for trauma – Authors' reply. Lancet, The, 2010, 376, 1050-1051.	6.3	190

#	Article	IF	Citations
163	Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet, The, 2010, 376, 23-32.	6.3	3,188
164	Patient outcome after traumatic brain injury in high-, middle- and low-income countries: analysis of data on 8927 patients in 46 countries. International Journal of Epidemiology, 2009, 38, 452-458.	0.9	222
165	Intracranial bleeding in patients with traumatic brain injury: A prognostic study. BMC Emergency Medicine, 2009, 9, 15.	0.7	116
166	Use of the Oxford Handicap Scale at hospital discharge to predict Glasgow Outcome Scale at 6 months in patients with traumatic brain injury. BMC Medical Research Methodology, 2008, 8, 72.	1.4	21
167	Predicting outcome after traumatic brain injury: practical prognostic models based on large cohort of international patients. BMJ: British Medical Journal, 2008, 336, 425-429.	2.4	950
168	Predicting Outcome after Traumatic Brain Injury: Development and International Validation of Prognostic Scores Based on Admission Characteristics. PLoS Medicine, 2008, 5, e165.	3.9	993
169	How effective are some common treatments for traumatic brain injury?. BMJ: British Medical Journal, 2008, 337, a865-a865.	2.4	11
170	Relation between the Global Burden of Disease and Randomized Clinical Trials Conducted in Latin America Published in the Five Leading Medical Journals. PLoS ONE, 2008, 3, e1696.	1.1	38
171	Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ: British Medical Journal, 2007, 334, 197.	2.4	630
172	Prognosis following head injury: a survey of doctors from developing and developed countries. Journal of Evaluation in Clinical Practice, 2007, 13, 464-465.	0.9	49
173	Systematic review of prognostic models in traumatic brain injury. BMC Medical Informatics and Decision Making, 2006, 6, 38.	1.5	273
174	Noncommunicable Diseases and Injuries in Latin America and the Caribbean: Time for Action. PLoS Medicine, 2006, 3, e344.	3.9	68
175	Household Wealth and the Metabolic Syndrome in the Whitehall II Study. Diabetes Care, 2006, 29, 2694-2700.	4.3	55
176	Evidence-Based Medicine in Iberoamerica: Problems and Possible Solutions. PLoS Medicine, 2005, 2, e277.	3.9	3
177	Research on preventing road traffic injuries in developing countries is needed. BMJ: British Medical Journal, 2004, 328, 895.1.	2.4	14
178	Studying accelerated cardiovascular ageing in Russian adults through a novel deep-learning ECG biomarker. Wellcome Open Research, 0, 6, 12.	0.9	8
179	An integrated community-based hypertension improvement program improves hypertension awareness in Ghana. Journal of Global Health Science, 0, 3, .	1.7	0
180	Factors Influencing the Implementation of Remote Delivery Strategies for Non-Communicable Disease Care in Low- and Middle-Income Countries: A Narrative Review. Public Health Reviews, 0, 43, .	1.3	3